EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER
Liver Cancer SUMMIT 20206-8 February 2020 Prague
N. Poster
Poster title
Applicant name
Status
 |
|
|
|
| P02-01 | Treatment-related toxicity predicts for improved outcome in patients with hepatocellular carcinoma (HCC) treated with immune checkpoint inhibitor therapy. | David J. Pinato |  Received |
 |
|||
| P07-01 | Intratumoral EpCAM-positive cancer stem cell heterogeneity in patients with hepatocellular carcinoma and its impact on clinical outcome | Johann von Felden | Received |
|
|||
| P03-01 | Tumor Burden Score: a useful tool to predict immune-related hepatotoxicity during immunotherapy in HCC | Antonio DAlessio | Received |
|
|||
| P06-01 | Circulating microRNA-21 and microRNA-122: prognosis prediction and correlation with HIF-1alpha in hepatocellular carcinoma patients treated with transarterial chemoembolization | Filippo Pelizzaro | Received |
|
|||
| P01-01 | Clinical Strategy of Diagnosing patients with Hepatocellular Carcinoma based on Latent Transforming Growth Factor-Beta Binding Protein 1 | Mohamed Abdel-Samiee | Received |
|
|||
| P04-01 | Application of BCLC-B subclassification and the Hong Kong Liver Cancer Systems to Intermediate Stage Hepatocellular Carcinoma | Coskun Ozer Demirtas | Received |
|
|||
| P05-01 | Hepatocellular Carcinoma in Non-Cirrhotic Liver Arises in a More Advanced Tumoral Appearance | Coskun Ozer Demirtas | Received |
|
|||
| P04-02 | Curative versus palliative treatments for recurrent hepatocellular carcinoma: an italian nationwide study | Francesca Carissimi | Received |
|
|||
| P03-02 | PIVKA-II is a useful biomarker for hepatocellular carcinoma in caucasian HCV cirrhotic patients treated with direct-acting antivirals | Elisabetta Degasperi | Received |
|
|||
| P06-02 | Metabolic rewiring in tumoral primary cholangiocytes: perspective for target therapy | Michela Anna Polidoro | Received |
|
|||
| P02-02 | Response rates to direct antiviral agents (DAA) among hepatitis C virus infected patients who develop hepatocellular carcinoma following DAA treatment | Alessandro Croce | Received |
|
|||
| P05-02 | Global characterisation of tumor infiltrate of Intrahepatic Cholangiocarcinoma by Sigle-Cell Sequencing | Ana Lleo | Received |
|
|||
| P07-02 | High rate of HBV S-integrated human ESPL1 fusion gene is detected in HBV-related liver cancer patients: A Chinese case-control study | Rongming Wang | Received |
|
|||
| OP01-02 | Deleting in vivo beta-catenin degradation domain in mouse hepatocytes drives hepatocellular carcinoma or mesenchymal hepatoblastoma similaryto Apc loss-of-function | Daniel Zaldumbide | Received |
|
|||
| P01-02 | Radiological and pathological characteristics associated with aggressive intrasegmental recurrence of hepatocellular carcinoma after radiofrequency ablation | marianne ziol | Received |
|
|||
| P07-03 | urinary epidermal growth factor-related transforming growth factors and serum alpha-fetoprotein as tumor markers of hepatocellular carcinoma | Jung-Fa Tsai | Received |
|
|||
| P02-03 | Hepatotoxicity during treatment with immune checkpoint inhibitors: what happens to the liver with tumor infiltration? | DAlessio Antonio | Received |
|
|||
| P04-03 | Association of single nucleotide polymorphisms for PNPLA3, Notch3 and EGF with hepatocellular carcinoma in alcohol-related liver disease | Anna Mrzljak | Received |
|
|||
| P01-03 | Hepatocellular Carcinoma: Most common presentation and its association with Portal vein thrombosis in different age groups | Muhammad Arsalan | Received |
|
|||
| P03-03 | External Validation of the Toronto Hepatocellular Carcinoma Risk Index in Turkish Cirrhotic Patients | Coskun Ozer Demirtas | Received |
|
|||
| P05-03 | Filamin-A expression predicts recurrence of mass-forming cholangiocarcinoma after hepatectomy | Flavio Milana | Received |
|
|||
| P06-03 | Circulating mir-4454 as a predictor of therapy response and disease-free survival in hepatocellular carcinoma | Muhammad Yogi Pratama | Received |
|
|||
| P03-04 | Deletion of erk5 protein kinase in myeloid cells impairs liver regeneration in mice | Giovanni Di Maira | Received |
|
|||
| P07-04 | Prognostic value of desmoplastic stroma in intrahepatic cholangiocarcinomas | nathalie guedj | Received |
|
|||
| P01-04 | randomized, open label, perioperative phase 2 study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable hcc | Ahmed Kaseb | Received |
|
|||
| P02-04 | Epidemiological trends of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease in Italy. On behalf of the ITA.LI.CA. study group | Alessandro Vitale | Received |
|
|||
| P06-04 | Characterization of novel oncogenic and tumor suppressor circRNAs in hepatocellular carcinoma | Rok Razpotnik | Received |
|
|||
| P05-04 | In vivo performance of PEG-coated gold nanoparticles mediated ultrasound guided radiofrequency ablation: a pilot study in swine | Tudor Mocan | Received |
|
|||
| P04-04 | DKK1 drives cholangiocarcinoma growth through modulation of the immune microenvironment | Ed Jarman | Received |
|
|||
| P03-05 | cfDNA in Hepatocellular Carcinoma | Ksenia Ellum | Received |
|
|||
| P06-05 | Prognostic role of a new index (PECS index) in advanced biliary tract cancer patients treated with first line chemotherapy: Training and Validation cohorts. | Giulia Rovesti | Received |
|
|||
| P07-05 | Clinical significance of serum albumin functional parameters for diagnosis of hepatocellular carcinoma | Rinat Gimadiev | Received |
|
|||
| P05-05 | New prognostic score utilizing glypican-3 serum levels for the prediction of 6-month outcome after transarterial therapies for patients with intermediate stage hepatocellular carcinoma | Anne Olbrich | Received |
|
|||
| P04-05 | Telomerase reverse transcriptase mutated circulating tumor DNA is a useful biomarker and predicts prognosis in Danish patients with hepatocellular carcinoma | Stine Karlsen | Received |
|
|||
| P01-05 | Prognostication of hepatocellular carcinoma under Sorafenib: external validation of the PROSASH-II model | Vito Sansone | Received |
|
|||
| P02-05 | Immunological approach to identify predictive factors for development of hepatocellular carcinoma in patients treated with direct-acting antivirals | Zuzana MACEK JILKOVA | Received |
|
|||
| P03-06 | The impact of postoperative ascites on survival after hepatectomy for hepatocellular carcinoma: A multicentric nation-based analysis | Simone Famularo | Received |
|
|||
| P06-06 | Hepatic lesion involvig the inferior vena cava: surgical management. | Pio Corleone | Received |
|
|||
| P02-06 | Interplay of PNPLA3 and HSD17B13 variants in modulating the risk of hepatocellular carcinoma among hepatitis C virus infected patients | Carla De Benedittis | Received |
|
|||
| P01-06 | Natural history of hepatobiliary hypointense-only found at magnetic resonance imaging with Gd-EOB-DTPA in cirrhotic patients: time-dependent effects of dimensional increase and diffusion weighted imaging alterations | Francesca Benevento | Received |
|
|||
| P05-06 | Distinct mechanisms are responsible for the activation of the NRF2-KEAP1 pathway at different steps of hepatocarcinogenesis | Amedeo Columbano | Received |
|
|||
| P07-06 | Salvage AALDLT for HCC beyond all criteria yield equivilant results to Milan criteria in high prevalence young HCC patients country. | Manar Salah | Received |
|
|||
| P04-06 | Clinical outcome of lenvatinib therapy in Japanese patients with unresectable hepatocellular carcinoma a nationwide multicenter study | Kaoru Tsuchiya | Received |
|
|||
| P01-07 | The concept of time-varying therapeutic hierarchy for patients with hepatocellular carcinoma: a multicenter cohort study. On behalf of the ITA.LI.CA. study group. | Alessandro Vitale | Received |
|
|||
| P03-07 | Biochemical and Clinical Evidence of Hepatocellular Carcinoma among Poorly Viral Suppressed ART Initiators in Southwestern Nigeria | Ayodeji Faremi | Received |
|
|||
| P04-07 | Umbelliferone loaded Nano-Lipidic Carrier exerts Diethylnitrosamine induced Hepatic Cancer via Attenuation of cellular inflammation and cell proliferation | efl2yjk6bo efl2yjk6bo | Received |
|
|||
| P06-07 | Multicenter validation of a scoring system to predict survival in biliary tract cancers receiving second-line chemotherapy | Massimiliano Salati | Received |
|
|||
| P02-07 | The NADPH oxidase NOX4 regulates lipid metabolism, which contributes to its tumor suppressor actions in hepatocellular carcinoma | Isabel Fabregat | Received |
|
|||
| P05-07 | Prognostic role of blood eosinophil count in sorafenib-treated hepatocellular carcinoma patients: time to reconsider the minorities | Giorgia Marisi | Received |
|
|||
| P07-07 | Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy. | David Pinato | Received |
|
|||
| P03-08 | Optimisation and qualification of tumour mutational burden (TMB) by targeted next-generation sequencing (tNGS) as a clinically applicable biomarker in hepatocellular carcinoma (HCC). | David Pinato | Received |
|
|||
| P04-08 | Stereotactic ablative radiotherapy in the management of metastatic and recurrent biliary tract cancer: single institution analysis of outcome and toxicity. | Ciro Franzese | Received |
|
|||
| P06-08 | The Six and Twelve score in a prospective cohort of patients with hepatocellular carcinoma treated with trans-arterial chemoembolization following a fixed schedule | Marco Sanduzzi Zamparelli | Received |
|
|||
| P02-08 | Regorafenib improves survival after sorafenib treatment in patients with recurrent hepatocellular carcinoma after liver transplantation, compared to best supportive care | Massimo Iavarone | Received |
|
|||
| P05-08 | Prevalence and impact of sarcopenia in patients undergoing liver transplantation for hepatocellular carcinoma | Ana Ostojic | Received |
|
|||
| P07-08 | Possible hepatoprotective effect of chlorogenic acid and protocatechuic acid combinational approach against diethylnitrosamine induced hepatocarcinogenesis in rodents as a multitargeted ligand | Ekta Yadav | Received |
|
|||
| P01-08 | Galactose Conjugated PPI Dendrimers for Liver targetting | Mani Bhargava | Received |
|
|||
| P05-09 | Dissecting a novel strategy to target Mitochondria in Bile Duct Cancers | Carotenuto Pietro | Received |
|
|||
| P04-09 | TREM2 protects the liver against hepatocellular carcinoma through multifactorial protective mechanisms | Ibone Labiano | Received |
|
|||
| P07-09 | Patient-led functional genomics identifies novel drivers of intrahepatic cholangiocarcinoma | Nicholas Younger | Received |
|
|||
| P02-09 | Nonalcoholic steatohepatitis is a risk factor for intrahepatic cholangiocarcinoma and affects its long-time outcome: results from a multicenter international case-control study | Stefania De Lorenzo | Received |
|
|||
| P01-09 | Major impact of personalised dosimetry using 90Y loaded glass microspheres SIRT in HCC: final Overal Survival analysis of a multicentre randomized phase II study. | Etienne Garin | Received |
|
|||
| P06-09 | Role of transient elastography in early detection of hepatocellular carcinoma in cirrhotic patients. | Abdel Ghani Badran | Received |
|
|||
| P03-09 | Developing high drug-load arsenic trioxide microsphere for chemoembolization of hepatocellular carcinoma | Gong Feng | Received |
|
|||
| P07-10 | NK-cell dysfunction in Hepatocellular Carcinoma: modulatory approches for functional restoration | Alessandra Zecca | Received |
|
|||
| P05-10 | Epidemiology, features and outcome of patients transplanted for hepatocellular carcinoma in the last decade: a single center experience | Federica Invernizzi | Received |
|
|||
| P04-10 | Novel protein biomarkers in serum extracellular vesicles for the diagnosis of cholangiocarcinoma in patients with primary sclerosing cholangitis: a mirror of the tumor features | Ainhoa Lapitz | Received |
|
|||
| P06-10 | Genetic variants do not predict the development of hepatocellular carcinoma in cross-sectional and longitudinal studies including caucasian compensated HBV cirrhotics treated with NUC for 10 years | Enrico Galmozzi | Received |
|
|||
| P02-10 | Albumin to gamma-glutamyltransferase and platelet to lymphocyte ratio do not predict recurrence and recurrence-free- survival after complete response to first-line HCC treatment | Alberta De Monti | Received |
|
|||
| P01-10 | Liquid Crystalline Nanoparticles based delivery of an Anticancer bioactive | Saurabh Bhargava | Received |
|
|||
| P03-10 | Evolution of indications for liver transplantation in the last 15 years: a single center experience in Madrid | Christie Perello | Received |
|
|||
| P03-11 | Pilot study of transarterial radioembolization with Yttrium-90 in patients with hepatocellular carcinoma | Pablo Florez-Díez | Received |
|
|||
| P07-11 | Safety Comparison between Drug-eluting Beads and Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma: A Multicentre Study | Lei Zhang | Received |
|
|||
| P04-11 | Does tumor size matter in intrahepatic cholangiocarcinoma? a population-based analysis | Xianwei Yang | Received |
|
|||
| P02-11 | A Retrospective Analysis of the Course of LI-RADS 3-4 Hepatic Lesions | Panita Mettikanont | Received |
|
|||
| P01-11 | Mitochondriotropic Carbon nanotubes for efficient Tumor Targetting | Varun Bhargava | Received |
|
|||
| P05-11 | Autoimmunity associated with primary biliray cholangitis prevents the development of cholangiocarcinoma in mouse models | Juliette Paillet | Received |
|
|||
| P06-11 | Circulating Small-RNA signature evidenced a susceptibility to HCC occurence in DAA-treated patients | Devis Pascut | Received |
|
|||
| P01-12 | Hepatic Uptake Index in the hepatobiliary phase of Gd-EOB-DTPA-enhanced magnetic resonance imaging estimates functional liver reserve and predicts post-hepatectomy liver failure | Bruno Branciforte | Received |
|
|||
| P07-12 | The combination of EpCAM-positive circulating tumor cells and serum AFP/AFP-L3/DCP predicts outcome after curative resection of hepatocellular carcinoma | Johann von Felden | Received |
|
|||
| P03-12 | Alpha Feta-Protein use as a standalone screening tool for hepatocellular carcinoma: single centre experience | Clare Foley | Received |
|
|||
| P02-12 | Early recurrence of hepatocellular carcinoma after liver transplantation can be predicted by FDG-PET and microvascular invasion at explant pathology | Federica Invernizzi | Received |
|
|||
| P06-12 | Therapy with DAA increases post-OLT survival but not the risk of recurrence in patients undergoing liver transplantation for HCV-related HCC | Vito Sansone | Received |
|
|||
| P05-12 | Mitochondrial oxidative metabolism contributes to maintain a cancer stem cell phenotype in cholangiocarcinoma | Mirella Pastore | Received |
|
|||
| P04-12 | c-Rel is a novel tumour suppressor and early prognostic indicator of hepatocellular carcinoma development | jack leslie | Received |
|
|||
| P05-13 | Association between survival of patients with hepatocellular carcinoma and 18F-fluoro-2-deoxy-D-galactose positron emission tomography/computed tomography | Kirstine Bak-Fredslund | Received |
|
|||
| P04-13 | Th therapeutic potential of adipose tissue-derived mesenchymal stem cells to enhance radiotherapy effects on hepatocellular carcinoma | Lingyun Wu | Received |
|
|||
| P01-13 | DNA damage response protein checkpoint kinase 2 (CHK2) links chromosomal instability to cellular metabolism in hepatocellular carcinoma (HCC) | Gianluca Bruno | Received |
|
|||
| P06-13 | Genetic risk factors of denovo hepatitis C-related hepatocellular carcinoma previously treated with direct acting antivirals | hend shousha | Received |
|
|||
| P07-13 | Long-term prospective study of development of hepatocellular carcinoma in compensated cirrhosis | Alessandra Pivetti | Received |
|
|||
| P03-13 | Feasibility of ultrasound-guided percutaneous biopsy in peri-hilar focal biliary lesions of the liver: a case series | Roberto Gabbiadini | Received |
|
|||
| P02-13 | A genetic risk score predicts de novo hepatocellular carcinoma in hepatitis C cirrhotic patients treated with direct-acting antivirals | Elisabetta Degasperi | Received |
|
|||
| P01-14 | Integrated phenotyping of the anti-cancer immune response in HIV-associated hepatocellular carcinoma | David Pinato | Received |
|
|||
| P07-14 | Characteristics of hepatocellular carcinoma post direct antiviral treatment of chronic hepatitis C patients : comparative study with non - direct - acting antivirals - treated patients | Mohamed Fathey Abdelkhalek Elgazzar | Received |
|
|||
| P02-14 | Programmed Cell Death-1 Gene Haplotypes are Associated with Hepatocellular Carcinoma | Coskun Ozer Demirtas | Received |
|
|||
| P04-14 | Serum lipidomic landscape of non-alcoholic fatty liver disease progression to hepatocellular carcinoma in a Caucasian population | Monika Lewinska | Received |
|
|||
| P03-14 | Dysregulation of aquaporin-1 in human CCA cells triggers epithelial-mesenchymal transition | CESAR GASPARI | Received |
|
|||
| P05-14 | Endothelial inducible T cell co-stimulator ligand (ICOSL) regulates adhesion molecule expression on liver endothelium: implications for senescence-mediated immune surveillance | Daniel Patten | Received |
|
|||
| P06-14 | Analysis of risk factors for survival and recurrence of hepatocellular carcinoma after liver transplantation | Petra Dinjar Kujundic | Received |
|
|||
| P03-15 | Tracking neutrophils within the hepatocellular carcinoma microenvironment - development of relevant orthotopic and ex-vivo 3D liver-HCC culture models | Daniel Geh | Received |
|
|||
| P06-15 | Radiological response to trans-arterial chemoembolisation (TACE) determines outcome in patients with hepatocellular carcinoma (HCC) | Nada Elamin | Received |
|
|||
| P01-15 | Prognostic significance of endocan and VEGF in the prediction of hepatocellular carcinoma in patients with compensated chronic viral hepatitis C-related cirrhosis | Jolanta Zuwala-Jagiello | Received |
|
|||
| P02-15 | Hepatocellular carcinoma in co-infected patients: more aggressive tumor behavior? | Lisa Rodrigues Da Cunha Saud | Received |
|
|||
| P07-15 | Common polymorphisms in the interleukin-1 beta gene are associated with HCV-related HCC in Caucasian patients | Janett Fischer | Received |
|
|||
| P05-15 | Activated platelets drive carcinogenesis and tumor growth in hepatocellular carcinoma | Natasa Pavlovic | Received |
|
|||
| P04-15 | Circulating levels of soluble urokinase plasminogen activator receptor (suPAR) predict outcome after resection of biliary tract cancer | Sven Loosen | Received |
|
|||
| P06-16 | miR-34a is activated in NAFLD and NASH-associated HCC, and correlates with key disease hallmarks | André Simão | Received |
|
|||
| P02-16 | A phase 3, randomized, double-blind, placebo-controlled study of transarterial chemoembolization combined with durvalumab (D) or durvalumab plus bevacizumab (B) therapy in patients (Pts) with locoregional hepatocellular carcinoma (HCC): EMERALD-1 | Humna Rizki | Received |
|
|||
| P07-16 | Incidence of indeterminate hepatic nodules in the preoperative magnetic resonance imaging in patients with colorectal cancer, their diagnosis, management and clinical outcome | Mizelle Dsilva | Received |
|
|||
| P03-16 | Impact of treatment with tenofovir alafenamide (TAF) or tenofovir disoproxil fumarate (TDF) on hepatocellular carcinoma (HCC) incidence in patients with chronic hepatitis B (CHB) | Leland Yee | Received |
|
|||
| P04-16 | Fatty acids regulate the biology of cholangiocarcinoma cells | Giulia Lori | Received |
|
|||
| P01-16 | Developing a bio-mimetic 3D model for hepatocellular carcinoma and the stromal micro-environment | Carlemi Calitz | Received |
|
|||
| P05-16 | Vascular invasion, portal vein thrombosis and dermatological events predict and prognosis the evolution and survival of patients with advanced hepatocellular carcinoma treated with sorafenib | Ioana Riaño | Received |
|
|||
| P02-17 | A novel test and treat hepatitis C micro-elimination project among underserved communities in Islamabad, Pakistan | Huma Qureshi | Received |
|
|||
| P03-17 | E2F1 and E2F2 regulate glycerophospholipid metabolism in nonalcoholic fatty-liver disease-related hepatocarcinogenesis | Francisco Gonzalez-Romero | Received |
|
|||
| P06-17 | A novel significance of apurinic/apyrimidinic endonuclease/redox effector factor 1 protein in hepatic cancer stem cells | Caecilia Sukowati | Received |
|
|||
| P04-17 | Role of the tandem SOX17-MRP3 in the poor response of cholangiocarcinoma to chemotherapy | Elisa Lozano | Received |
|
|||
| P07-17 | Risk of developing hepatocellular carcinoma in patients with cirrhosis of viral etiology evaluated by the combination of alpha-fetoprotein, protein induced by vitamin K absence or antagonist-II and glypican-3 | Michela Ciruolo | Received |
|
|||
| P01-17 | Identification of a proteomic signature in advanced hepatocellular carcinoma predicting response to sorafenib | Frederic Saltel | Received |
|
|||
| P05-17 | Hepatotoxicity from immune-checkpoint inhibition in the treatment of hepatocellular carcinoma: outcomes and tissue biomarker analysis | Nicola Personeni | Received |
|
|||
| P05-18 | Serum metabolic biomarkers for the differential diagnosis of distal cholangiocarcinoma and pancreas ductal adenocarcinoma | Ana Peleteiro Vigil | Received |
|
|||
| P04-18 | Comparison between stratification system for liver cancer BCLC and HKLC-5 as a predictor of mortality in a university hospital cohort in Chile | Rodrigo Wolff | Received |
|
|||
| P07-18 | Composite targeting of nuclear receptors protects mice from NAFLD progression towards HCC | Tawhidul Islam | Received |
|
|||
| P06-18 | Empowerment of liver cancer patients for an improved management of post-embolization syndrome: Impact of a Nurses Educational program | Neus Llarch | Received |
|
|||
| P01-18 | The volume of enhancement of disease (VED) predicts the early response to treatment and overall survival in patients with advanced hepatocellular carcinoma treated with sorafenib | Claudia Campani | Received |
|
|||
| P02-18 | Regulation of the biology of cholangiocarcinoma (CCA) cells by extracellular-signal regulated kinase 5 (ERK5) | Giovanni Di Maira | Received |
|
|||
| P03-18 | Surveillance improves survival of intrahepatic cholangiocarcinoma arisen in liver cirrhosis | Pietro Guerra | Received |
|
|||
| P05-19 | SCCA-IgM predicts prognosis differently according to gender in hepatocellular carcinoma patients treated with transarterial chemoembolization | Filippo Pelizzaro | Received |
|
|||
| P02-19 | A Blood-Based DNA Methylation Test for Early Detection of Hepatocellular Carcinoma | Dhruvajyoti Roy | Received |
|
|||
| P01-19 | Development of diet-induced NASH/HCC model in Sprague Dawley rats. | Lydie Carreres | Received |
|
|||
| P06-19 | SImBA: a user-friendly high throughput tool for spheroid invasion analysis of hepatocellular carcinoma cell lines | Elias Van De Vijver | Received |
|
|||
| P03-19 | Inactivation of the BAP1 tumor suppressor defines a subgroup of hepatocellular carcinoma with fibrolamellar features | Theo Hirsch | Received |
|
|||
| P04-19 | Magnetic resonance of hepatocellular carcinoma treated with radiofrequency ablation: Radiomics to predict treatment response - preliminary results | Claudia Maccali | Received |
|
|||
| P07-19 | Variable expression of venous clot coordinator high mobility group box-1 in patients with hepatocellular carcinoma with or without portal vein thrombosis | Erica Matino | Received |
|
|||
| P03-20 | Targeting antiapoptotic proteins Bcl-xL and Mcl-1 in cholangiocarcinoma | Paula Katharina Morgane Hoffmeister | Received |
|
|||
| P04-20 | PARP-1 inhibition preferentially impairs KRAS-mutated intrahepatic cholangiocarcinoma and induces distinct molecular alterations | Friederike Mahn | Received |
|
|||
| P05-20 | Differential Role of TGF-Beta1&2 on Proliferative and Invasive Properties in Primary Liver Cancer | Sharon Pereira | Received |
|
|||
| P02-20 | miRNA profiling of biliary intraepithelial neoplasia reveals step-wise tumorigenesis in distal cholangiocarcinoma via the miR-451a/ATF2 axis | Stephanie Roessler | Received |
|
|||
| P01-20 | Portal hypertension and sequential bilobar treatment increase risk of hepatic decompensation in patients with hepatocellular carcinoma treated with 90Yttrium radioembolization | Laura Carrion | Received |
|
|||
| P06-20 | Involvement of the glycan-binding protein galectin-1 in hepatocellular carcinoma cell drug resistance | María Fernanda Troncoso | Received |
|
|||
| P04-21 | Inhibitory effects of butyrate carrier structured lipids on persistent preneoplastic lesions induced by the resistant hepatocyte model of hepatocarcinogenesis | Juliana Marques Affonso | Received |
|
|||
| PB07-21 | SBRT vs TAE/TACE in Hepatocellular carcinoma: results from a Phase III trial (NTC02323360) | Tiziana Comito | Received |
|
|||
| P07-21 | Advances in serum biomarkers for primary and secondary liver carcinomas | Marie Karlikova | Received |
|
|||
| P03-21 | Protective role of aspirin chronic assumption in patients treated with sorafenib for hepatocellular carcinoma | Luca Ielasi | Received |
|
|||
| P02-21 | plasma circulating cell-free DNA integrity is a risk factor of denovo hepatitis-C related hepatocellular carcinoma treated or not with direct acting antiviral therapy | hend shousha | Received |
|
|||
| P05-21 | Critical modifications of ganglioside patterns in human cholangiocarcinoma | Benedetta Piombanti | Received |
|
|||
| P01-21 | Targeting tumor-initiating cells as an effective approach to overcome sorafenib resistance in hepatocellular carcinoma | Darko Castven | Received |
|
|||
| P06-21 | Transcriptome profiling of liver biopsies before antiviral treatment start can predict HCC development 8.3 years before clinical diagnosis in chronic Hepatitis B and C patients | Stijn Van Hees | Received |
|
|||
| P05-22 | Applicability of Six and Twelve model in patients with hepatocellular carcinoma treated with DEB-TACE | Maria Pipa Muñiz | Received |
|
|||
| PB07-22 | Inhibiting endoplasmic reticulum stress in hepatic stellate cells decreases the progression of hepatocellular carcinoma | Natasa Pavlovic | Received |
|
|||
| P02-22 | The role of stereotactic body radiation therapy in the management of hepatocellular carcinoma: outcome and toxicity from a single institution experience. | Ciro Franzese | Received |
|
|||
| P06-22 | ZEB1 promotes cholangiocarcinoma progression through tumor dedifferentiation and paracrine signalling between tumor cells and cancer-associated fibroblasts | Javier Vaquero | Received |
|
|||
| P01-22 | Characterisation of a plasmid-based mouse model of liver cancer with concomitant liver injury | Vincent Chiu | Received |
|
|||
| P04-22 | Application of serum cytokeratin-19 fragments (CYFRA 21-1) in predicting the prognosis of patients with hepatocellular carcinoma | Michela Ciruolo | Received |
|
|||
| P03-22 | Impact of a Nurse Educational program for patients empowerment during sequential systemic therapy for hepatocellular carcinoma | Gemma Iserte Fort | Received |
|
|||
| PB04-23 | Specific RNA profiles in serum and urine extracellular vesicles of patients with cholangiocarcinoma mimicking tumor tissue and cell expression: a novel liquid biopsy approach | Ainhoa Lapitz | Received |
|
|||
| PB07-23 | Clinical activity of cabozantinib in patients with advanced hepatocellular carcinoma previously treated with anti-VEGF and immuno-oncology therapy: subgroup analysis from the phase 3 CELESTIAL trial | Jennifer Humbert | Received |
|
|||
| PB05-23 | miR-21 is increased in patients with NASH-associated HCC and contributes to hepatocarcinogenesis in mice with NAFLD | Pedro Miguel Rodrigues | Received |
|
|||
| P01-23 | The role of endosonography and endosonography guided fine needle aspiration in detection of small sized liver metastasis in patients with pancreatic and gastro-intestinal malignancy | Saeed M. El-Nahaas | Received |
|
|||
| P02-23 | Development of personalised human immunocompetent ex vivo models of primary and secondary liver cancers using precision cut tissue slice technology | Ewald Doornebal | Received |
|
|||
| PB03-23 | Neoangiogenic transcriptomic signature identifies HCCs with worse response to treatment: long-term results of a prospective study | Erica Villa | Received |
|
|||
| PB05-24 | Hepatic RIPK3 signalling differentially modulates lipid metabolism and inflammation/carcinogenesis in non-alcoholic steatohepatitis | Marta B. Afonso | Received |
|
|||
| PB07-24 | Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab/placebo: results from two randomised phase 3 trials (REACH/REACH-2) | Peter Galle | Received |
|
|||
| PB03-24 | Quantitative magnetic resonance imaging predicts individual future liver performance after liver resection for cancer. | John Connell | Received |
|
|||
| PB04-24 | Predicting survival after hepatocellular carcinoma resection using deep-learning on histological slides | Julien Calderaro | Received |
|
|||
Liver Cancer SUMMIT 2020
6-8 February 2020 Prague
Search and consult posters online
in an exclusive section
for each poster
in an exclusive section
for each poster
ACTIVE FROM 06/02/2020 TO 06/02/2021
Poster
Gallery
Gallery
Upload
Poster
Poster
Featured Poster
Vote poster
Poster Discussion
Forum
Forum
|
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress.
|
|
||
|
||||
|
|
